PURE-02: An open-label, single-arm, feasibility study of neoadjuvant pembrolizumab before Radical Nephroureterectomy (RNU) in patients with high-risk, Upper-Tract Urothelial Carcinoma (UTUC)
Authors:
- 1 June 2021
- journal article
- Published by Elsevier in European Urology
- Vol. 79, S1089